Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 20.0-60.0,  Asthma Healthy male adults aged between 20 and 60 years inclusive Healthy as determined by a responsible physician, based on a medical evaluation including history, physical examination, laboratory tests, and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator considers that the finding will not introduce additional risk factors and will not interfere with the study procedures Male subjects must use double-barrier (condom/spermicide) birth control methods or abstain from sexual intercourse with female partners who are pregnant, lactating, or able to bear children in addition to any birth control method the female partner is using, from the first dose of study medication until 90 days after the last dose of study medication Japanese ethnic origin (defined as having been born in Japan with four ethnic Japanese grandparents and able to speak Japanese) Body weight ≥ 45 kg and body mass index within the range of 18-28 kg/m2 inclusive No significant abnormality on 12-lead ECG at screening, including the following specific requirements Ventricular rate ≥ 45 beats per minute PR interval ≤ 210msec Q waves < 30msec (up to 50 ms permitted in lead III only) QRS interval to be ≥ 60msec and ≤ 120msec  As a result of medical interview, physical examination or screening investigations, the principle investigator or delegate physician deems the subject unsuitable for the study. Subjects must not have a systolic blood pressure above 145 mmHg or a diastolic pressure above 85 mmHg unless the Investigator confirms that it is satisfactory for their age The subject has been treated for or diagnosed with depression within six months of screening or has a history of significant psychiatric illness Subjects who have suffered an upper or lower respiratory tract infection within 4 weeks of the screening visit Liver function tests (AST, ALT or ALP) greater than 1.5 of the upper limit of laboratory reference range History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation History of milk protein allergy The subject has taken prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is the longer) prior to the first dose of study medication, unless in the opinion of the Investigator and Sponsor the medication will not interfere with the study procedures or compromise subject safety The subject has taken oral corticosteroids less than 8 weeks before the screening visit The subject has taken inhaled, intranasal or topical steroids less than 4 weeks before the screening visit History of alcohol/drug abuse or dependence within 12 months of the study